Table 1.
J |
J+J |
P |
P+P |
J+P |
|||
---|---|---|---|---|---|---|---|
Characteristics | Ad26.COV2.S, single dose | Ad26.COV2.S, double dose | BNT162b2, single dose | BNT162b2, double dose | Ad26.COV2.S and BNT162b2 | Total | Statistical analysisa |
No. of participants | 13 | 28 | 16 | 44 | 14 | 115 | N/A |
Sexb | |||||||
Male (%) | 6 (46.2) | 18 (64.2) | 7 (43.7) | 15 (34.1) | 9 (64.3) | 55 (47.8) | no statistical difference |
Female (%) | 7 (53.8) | 10 (35.8) | 9 (56.3) | 29 (65.9) | 5 (35.7) | 60 (52.1) | no statistical difference |
Infection statusb | |||||||
Naïve (%) | 12 (92.3) | 23 (82.1) | 10 (62.5) | 37 (84.1) | 9 (64.3) | 91 (79.1) | no statistical difference |
Infected (%) | 1 (7.7) | 5 (17.9) | 6 (37.5) | 7 (15.) | 5 (35.7) | 24 (20.9) | no statistical difference |
Agec | |||||||
Mean, years | 39.2 | 51.2 | 42.8 | 42 | 45.5 | 44.2 | J and J+J∗ |
Range, years | 25–69 | 25–75 | 32–53 | 23–62 | 25–70 | 23–75 | J+J and P+P∗ |
Days between prime and boost | |||||||
Median | – | 57 | – | 21 | 42 | – | N/A |
Range | – | 43–71 | – | 21–104 | 11–180 | – | N/A |
Days post-last dose | |||||||
Median | 80 | 49.5 | 60 | 94 | 32 | 77.5 | N/A |
Range | 23–169 | 21–164 | 22–78 | 21–151 | 21–124 | 7–169 | N/A |
Race or ethnic group | |||||||
White (other/British/Irish) (%) | 11 (84.6) | 21 (75) | 8 (50) | 5 (11.4) | 11 (75.6) | 56 (48.7) | N/A |
Black (%) | 1 (7.6) | – | – | – | – | 1 (0.9) | N/A |
Asian or South Asian (Indian/Chinese/other) (%) | 1 (7.6) | 4 (14.3) | 6 (37.5) | 36 (81.8) | 2 (14.3) | 49 (42.6) | N/A |
Caucasian/mixed/others (%) | – | 2 (7.2) | 1 (6.2) | 3 (6.8) | 1 (7.1) | 7 (6.1) | N/A |
Unknown/undisclosed (%) | – | 1 (3.5) | 1 (6.2) | – | – | 2 (1.7) | N/A |
Statistical analysis was carried out where applicable. ∗p ≤ 0.05. NA, not applicable.
Only results shown for significant multiple comparisons.
Chi-square test was used.
One-way ANOVA was used.